Add to Basket
Order hotline:
![]() |
+1 404 474 4654 |
![]() |
+1 888 205 9894 (TF) |
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) antibody
| Antigen | Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) |
| Synonyms | CEA, CD66e, DKFZp781M2392, Psg30, 1600029H12Rik, CEACAM5, CEACAM |
| Clonality | Monoclonal (26-5-1) |
| Host |
Alternatives Mouse |
| Reactivity |
Alternatives Human |
| Application |
Alternatives Flow Cytometry (FACS), Immunohistochemistry (IHC), Cell-ELISA (cELISA), Western Blotting (WB), ELISA
|
![]() |
4 references available |
| Catalog no. | ABIN108734 |
| Quantity | 100 ug (1 mg/ml) |
| Price | 594.29 $ Plus shipping costs $35.00 |
| Shipping to |
|
| Availability | Ships within 3 to 5 Business days |
Additional Information
| Alternative name | CEACAM5 (CEA, CD66e) |
| Immunogen | Immunisation with extracted protein of CEACAM5. Selection based on recognition of the complete native protein expressed on transfected mammalian cells |
| Format | Purified |
| Isotype | IgG2a |
| Clone | 26-5-1 |
| Description | CEACAM5 (CEA-related cell adhesion molecule 5, CEA) belongs to the carcinoembryonic antigen (CEA) gene family (2). It encodes a glycosyl phosphatidyl inositol (GPI)-linked glycoprotein with a Mr of 180,000-200,000 which is most strongly expressed on epithelial cells of the fetal and adult colon and to a minor extent on epithelial cells of the stomach and sweat glands, squamous epithelial cell of the tongue, esophagus and cervix. CEACAM5 is used as a tumor marker for early detection of recurrent disease due its expression in adenocarcinomas of the colon, lung, breast, stomach and pancreas and in mucinous ovarian carcinomas (2). Like all members of the CEACAM family, it consists of a single N domain, with structural homology to the immunoglobulin variable domains, followed by six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3). |
| Specificity | Anti-human CEACAM5 (CEA, CD66e) |
Application Details
| Application Notes | Flow cytometry (1.2 ug/10^6 cells), cell-ELISA (1:200), ELISA (1:200 - 1:400), Western blots (4ug/ml) and immunohistology on cryosections (1-2 ug/10^6 cells). |
| Concentration | 1 mg/ml |
| Buffer | phosphate buffered saline, pH 7.2 |
| Storage | Short term: 2°C - 8°C. Long term: -20°C (avoid repeated freezing and thawing) |
| Research Area | Receptors, Cancer, Receptors, Cell/Tissue Markers, Cancer |
| Restrictions | For Research Use only |
Images
Publications
| Publications |
Manosroi, von Kleist, Manosroi et al.: "Thermo-stability and antitumor activity on colon cancer cell lines of monoclonal anti-CEA antibody-saporin immunotoxin." in: Journal of Korean medical science, Vol. 7, Issue 2, pp. 128-35, 1992 (PubMed).
Hammarstrom, Shively, Paxton et al.: "Antigenic sites in carcinoembryonic antigen." in: Cancer research, Vol. 49, Issue 17, pp. 4852-8, 1989 (PubMed). Strobel ES, Strobel HG, Bross KJ et al.: "Effects of human bone marrow stroma on the growth of human tumor cells." in: Cancer Res, Vol. 49, Issue 4, pp. 1001-7, 1989 (PubMed). Grunert, AbuHarfeil, Schwarz et al.: "Two CEA and three NCA species, although distinguishable by monoclonal antibodies, have nearly identical peptide patterns." in: International journal of cancer. Journal international du cancer, Vol. 36, Issue 3, pp. 357-62, 1985 (PubMed). |
Alternatives
Alternatives for antigen "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5)", type "Antibodies"
| Hosts | Mouse (67), Rabbit (13), Goat (1) |
| Reactivities | Human (77), Mouse (Murine) (1) |
| Applications | Immunohistochemistry (Frozen Sections) (IHC (fro)) (37), Enzyme Immunoassay (EIA) (34), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (32), Western Blotting (WB) (25), Flow Cytometry (FACS) (17), Immunofluorescence (IF) (7), Immunoprecipitation (IP) (7), ELISA (Detection) (3), ELISA (2), Radioimmunoassay (RIA) (2), Cell-ELISA (cELISA) (1), Immunohistochemistry (IHC) (1) |
| Conjugates | FITC (3), HRP (1) |
| Epitopes | Group I (4), Center (1), Group IV (1), Group IVa or II (1) |




Alternatives